PMID | Genes# | Samples Size | Ethnicity | Traits | P-values | NGS Type | Analysis |
---|---|---|---|---|---|---|---|
32111823 | 3 | GWAS: HF = 24,829 Controls = 1,614,513 | European | Ischemic heart disease: myocardial infarction, percutaneous coronary intervention or coronary artery bypass graft surgery; HF | P < 5E−8 | RNA-seq | Mendelian randomization (MR Egger), linear regression |
29717556 | 1 | HF = 3 | St. Louis (USA), Ghent (Belgium) | Bilateral inguinal hernia correction; retropatellar cartilage problems, verapamil for symptomatic ventricular extrasystoles | N/A | N/A | Echocardiography |
34327238 | 1 | GWAS: HF = 191 | Asian, American, African, European | Cancer patients who received adjuvant doxorubicin therapy | P = 5.63E−5, P = 5.70E−5 | N/A | GraphPad Prism, Linear Regression model |
31919418 | 14 | GWAS: HF = 47,309 Controls = 930,014 | European | HF | p < 5E−8 | RNA-seq | Two-sample MR, Mendelian randomization (MG Egger) |
29457789 | 1 | HF = 1,659 | European, African-American | Cardiomyopathy patients with implantable cardioverter defibrillators (ICDs) | p < 5E−2 | RNA-seq (by Illumina truSEq and Nugen Ovation) | GraphPad, Fisher's exact test, ANOVA |
31554410 | 8 | GWAS: HF = 16,923 | European | Myocardial infarction or HF | 1.50E−05 | N/A | LDPred tool (used to obtain PRS), CMR protocol and analysis methods |